Influence of drug treatment of symptomatic uterine leiomyoma on the quality of life of women

Close metadata

Recommended articles:

Benign breast diseases in the focus of proliferative pathology of the reproductive system. Russian Journal of Human Reproduction. 2024;(3):33-42

A clinical case of parasitic fibroids on the mesentery of the sigmoid colon. Russian Journal of Human Reproduction. 2024;(3):105-110

Tolerability of multiphasic and monophasic combined hormonal contraceptives patients with uterine fibroids. Russian Journal of Human Reproduction. 2024;(4):78-89

Heterogeneity of the molecular phenotype with uterine fibroids. Message I. Russian Journal of Human Reproduction. 2024;(4):121-130

Heterogeneity of the molecular phenotype with uterine fibroids. Message II. Russian Journal of Human Reproduction. 2024;(5):15-24

Controversial issues of adjuvant therapy after myomectomy. Russian Bulletin of Obstetrician-Gynecologist. 2024;(5):101-107

Structural and biochemical features of menstrual discharge in patients with uterine fibroids. Russian Bulletin of Obstetrician-Gynecologist. 2024;(6):85-90

The practice of using medical abortion in the world. Russian Bulletin of Obstetrician-Gynecologist. 2025;(1):19-24

The article is devoted to the possibilities of drug therapy for uterine fibroids, using selective modulators of progesterone receptors. It is shown that mifepristone — the ancestor of this group of drugs, discovered in the 80s of the last century, is the most studied and promising molecule, the interest to which is not weakening: the effect of mifepristone, including on the breast tissue, is also being studied. Mifepristone (gynestril) is characterized by its effectiveness and high level of safety in the treatment of patients with uterine fibroids.

Keywords:

uterine fibroids

mifepristone

selective modulators of progesterone receptors

gynestril

Authors:

Tapil'skaia N.I.

Sankt-Peterburgskaia gosudarstvennaia pediatricheskaia meditsinskaia akademiia

Dukhanin A.S.

Pirogov Russian National Research Medical University, Department of Molecular Pharmacology and Radiobiology, Moscow, Russia

Glushakov R.I.

Voenno-meditsinskaia akademiia im. S.M. Kirova

List of references:

Hasserlot K, Lissenberg M, Konings P, Kallner HK. Investigating the loss of work productivity due to symptomatic leiomyoma. PloS One. 2018;13(6):e0197958. https://doi.org/10.1371/journal.pone.0197958
Mioma matki: diagnostika, lechenie, reabilitatsiya. Klinicheskie rekomendatsii (protokol lecheniya). M. 2015. Accessed Julay 7, 2018. Available at: http://docs.cntd.ru/document/456019539 (In Russ.)
Ezzati M, Norian JM, Segars JH. Management of uterine fibroids in the patient pursuing assisted reproductive technologies. Womens Health. 2009;5(4):413-421. https://doi.org/10.2217/whe.09.29
Brahma PK, Martel KM, Christman GM. Future directions in myoma research. Obstetrics and Gynecology Clinics of North America. 2006;33(1):199-224.
Vercellini P, Za`ina B, Yaylayan L, Pisacreta A, De Giorgi O, Crosignani PG. Hysteroscopic myomectomy: long-term effects on menstrual pattern and fertility. Obstetrics and Gynecology. 1999;94(3):341-347.
Eseneeva FM. Ehpigeneticheskie determinanty miomy matki: Dis... kand. med. nauk. M. 2018. Accessed Julay 7, 2018. Available at: https://dissovet.rudn.ru/web-local/prep/rj/dis/download.php?file=f053ca670e6ae7b58e6064dbf67958d926089 (In Russ.)
Viville B, Charnock-Jones DS, Sharkey AM, Wetzka B, Smith SK. Distribution of the A and B forms of the progesterone receptor messenger ribonucleic acid and protein in uterine leiomyomata and adjacent myometrium. Human Reproduction. 1997;12(4):815-822.
Brandon DD, Bethea CL, Strawn EY, Novy MJ, Burry KA, Harrington MS, Erickson TE, Warner C, Keenan EJ, Clinton GM. Progesterone receptor messenger ribonucleic acid and protein are overexpressed in human uterine leiomyomas. American Journal of Obstetrics and Gynecology. 1993;169(1):78-85.
Nisolle M, Gillerot S, Casanas-Roux F, Squifflet J, Berliere M, Donnez J. Immunohistochemical study of the proliferation index, oestrogen receptors and progesterone receptors A and B in leiomyomata and normal myometrium during the menstrual cycle and under gonadotrophin-releasing hormone agonist therapy. Human Reproduction. 1999;14(11):2844-2850.
Englund K, Blanck A, Gustavsson I, Lundkvist U, Sjöblom P, Norgren A, Lindblom B. Sex steroid receptors in human myometrium and fibroids: changes during the menstrual cycle and gonadotropin-releasing hormone treatment. The Journal of Clinical Endocrinology and Metabolism. 1998;83(11):4092-4096.
Leonhardt SA, Boonyaratanakornkit V, Edwards DP. Progesterone receptor transcription and non-transcription signaling mechanisms. Steroids. 2003;68(10-13):761-770.
McEwan IJ. Nuclear receptors: one big family. Methods in Molecular Biology. 2009;505:3-18.
Maruo T, Ohara N, Matsuo H, Xu Q, Chen W, Sitruk-Ware R, Johansson ED. Effects of levonorgestrel-releasing IUS and progesterone receptor modulator PRM CDB-2914 on uterine leiomyomas. Contraception. 2007;75(6 suppl):99-103.
Kato J, Kitamura K. Bench-to-bedside pharmacology of adrenomedullin. European Journal of Pharmacology. 2015;764:140-148. https://doi.org/10.1016/j.ejphar.2015.06.061
Shimomura Y, Matsuo H, Samoto T, Maruo T. Up-regulation by progesterone of proliferating cell nuclear antigen and epidermal growth factor expression in human uterine leiomyoma. The Journal of Clinical Endocrinology and Metabolism. 1998;83(6):2192-2198.
Fritsch M, Schmidt N, Gröticke I, Frisk AL, Keator CS, Koch M, Slayden OD. Application of a patient derived xenograft model for predicative study of uterine fibroid disease. PloS One. 2015;10(11): e0142429. https://doi.org/10.1371/journal.pone.0142429
Mavrelos D, Ben-Nagi J, Holland T, Hoo W, Naftalin J, Jurkovic D. The natural history of fibroids. Ultrasound in Obstetrics and Gynecology. 2010;35(2):238-242. https://doi.org/10.1002/uog.7482
Peddada SD, Laughlin SK, Miner K, Guyon JP, Haneke K, Vahdat HL, Semelka RC, Kowalik A, Armao D, Davis B, Baird DD. Growth of uterine leiomyomata among premenopausal black and white women. Proceedings of the National Academy of Sciences of the United States of America. 2008;105(50):19887-19892. https://doi.org/10.1073/pnas.0808188105
Taylor HS, Bagot C, Kardana A, Olive D, Arici A. HOX gene expression is altered in the endometrium of women with endometriosis. Human Reproduction. 1999;14(5):1328-1331.
Sinclair DC, Mastroyannis A, Taylor HS. Leiomyoma simultaneously impair endometrial BMP-2-mediated decidualization and anticoagulant expression through secretion of TGF-β3. The Journal of Clinical Endocrinology and Metabolism. 2011;96(2):412-421.
Cubellis MV, Wun TC, Blasi F. Receptor-mediated internalization and degradation of urokinase is caused by its specific inhibitor PAI-1. The EMBO Journal. 1990;9(4):1079-1085.
Lwaleed BA, Greenfield R, Stewart A, Birch B, Cooper AJ. Seminal clotting and fibrinolytic balance: a possible physiological role in the male reproductive system. Thrombosis and Haemostasis. 2004;92(4):752-766.
Bouchard P, Chabbert-Buffet N, Fauser BC. Selective progesterone receptor modulators in reproductive medicine: pharmacology, clinical efficacy and safety. Fertility and Sterility. 2011;96(5):1175-1189. https://doi.org/10.1016/j.fertnstert.2011.08.021
Wagenfeld A, Saunders PT, Whitaker L, Critchley HO. Selective progesterone receptor modulators (SPRMs): progesterone receptor action, mode of action on the endometrium and treatment options in gynecological therapies. Expert Opinion on Therapeutic Targets. 2016;20(9):1045-1054. https://doi.org/10.1080/14728222.2016.1180368
Dale MM, Rang HP, Dale Maureen M. Rang and Dale’s Pharmacology. Edinburgh: Churchill Livingstone; 2007.
Liu Z, Auboeuf D, Wong J, Chen JD, Tsai SY, Tsai MJ, O’Malley BW. Coactivator/corepressor ratios modulate PR-mediated transcription by the selective receptor modulator RU486. Proceedings of the National Academy of Sciences of the United States of America. 2002;99(12):7940-7944.
Horak P, Mara M, Dundr P, Kubinova K, Kuzel D, Hudecek R, Chme R. Effect of a selective progesterone receptor modulator on induction of apoptosis in uterine fibroids in vivo. International Journal of Endocrinology. 2012;2012:436174. https://doi.org/10.1155/2012/436174
Goyeneche AA, Telleria CM. Antiprogestins in gynecological diseases. Reproduction. 2015;149(1):15-33. https://doi.org/10.1016/j.ijgo.2009.11.019
Murphy AA, Kettel LM, Morales AJ, Roberts VJ, Yen SS. Regression of uterine leiomyomata in response to the antiprogesterone RU 486. The Journal of Clinical Endocrinology and Metabolism. 1993;76(2):513-517.
Sabry M, Al-Hendy A. Innovative oral treatments of uterine leiomyoma. Obstetrics and Gynecology International. 2012;2012:943635. https://doi.org/10.1155/2012/943635
Goyeneche AA, Seidel EE, Telleria CM. Growth inhibition induced by antiprogestins RU-38486, ORG-31710, and CDB-2914 in ovarian cancer cells involves inhibition of cyclin dependent kinase 2. Investigational New Drugs. 2012;30(3):967-980. https://doi.org/10.1007/s10637-011-9655-z
Johanssen S, Allolio B. Mifepristone (RU 486) in Cushing’s syndrome. European Journal of Endocrinology. 2007;157(5):561-569.
Nuclear Receptors as Drug Targets: Design and Biological Evaluation of Small Molecule Modulators of Nuclear Receptor Action. ProQuest. 2006.
Informatsiya s saita FDA. Accessed April 21.04.18. Available at: https://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/DevelopmentResources/UCM295394.pdf
Engman M, Skoog L, Soderqvist G, Gemzell-Danielsson K. The effect of mifepristone on breast cell proliferation in premenopausal women evaluated through ﬁne needle aspiration cytology. Human Reproduction. 2008;23(9):2072-2079.
Tieszen CR, Goyeneche AA, Brandhagen BA, Ortbahn C, Telleria CM. Antiprogestin mifepristone inhibits the growth of cancer cells of reproductive and non-reproductive origin regardless of progesterone receptor expression. BioMed Central Cancer. 2011;11:207. https://doi.org/10.1186/1471-2407-11-207
Feng C, Meldrum S, Fiscella K. Improved quality of life is partly explained by fewer symptoms after treatment of fibroids with mifepristone. International Journal of Gynaecology and Obstetrics. 2010;109(2):121-124. https://doi.org/10.1016/j.ijgo.2009.11.019
Tristan M, Orozco LJ, Steed A, Ramírez-Morera A, Stone P. Mifepristone for uterine fibroids. The Cochrane Database of Systematic Reviews. 2012;8:CD007687. https://doi.org/10.1002/14651858.CD007687
Shen Q, Hua Y, Jiang W, Zhang W, Chen M, Zhu X. Effects of mifepristone on uterine leiomyoma in premenopausal women: a meta-analysis. Fertility and Sterility. 2013;100(6):1722-6.e1-10. https://doi.org/10.1016/j.fertnstert.2013.08.039
Tapilskaya NI, Gaidukov SN. Clinical efficacy of mifepristone in patients with uterine myoma. Zhurnal akusherstva i zhenskikh boleznei. 2005;LIV(4):65-68. (In Russ.)
Samojlova TE. Pharmacotherapy of uterine leiomyoma with antigestagens: opportunities and prospects. Ginekologiya. 2011;3:12-18. (In Russ.)
Fatkullin IF, Bakanova AR, Ilizarova NA, Galeev AA. New treatment options for women with uterine leiomyoma and reproductive disorders. Doktor.Ru. 2016;8-9(125-126):32-37. (In Russ.)

Close metadata